Another Jacko
25 Mar 2018
Times article There's a small article in the Times about Angle this morning.[link]
Profitcruncher
06 Mar 2018
Movement At last, some movement. I reckon a RNS due updating about results of trials. I could be wrong and it could be update on FDA position. fingers crossed.
claude reins
19 Jan 2018
News from US on blood test potential See [link] This test process has been used on a number of cancer patients often with types of cancers which have not been able to be detected early in the past eg pancreas. This test SO FAR is on cancer sufferers, and has not been tested on the most important element, early detection. That is where AGL is so strong, though they are concentrating on breast and prostate cancers.Difficult to know what effect on AGL's prospects. My view is that because it is so far advanced, then the increased focus on blood testing and promise from it will be beneficial for AGL.Therefore I have it as a buy, and probably this strengthens the case for a company like Philips to take it over in the nearer future than before.
millwallfan
16 Jan 2018
Rns Good PR from independent source but no move up
claude reins
09 Jan 2018
The strange thing about this share....... ......is that there is a rise in SP following good news, and then literally the following day, there is a sell off - not vast numbers but significant in the context of this stock - which sends the SP back down again. Why anyone should sell over 20,000 shares todya is beyond my ken. Anyone else's 'ken' can explain this?
autpaxautbellum
08 Jan 2018
Re: The benefits keep pouring in......... Agree Claude - we’ll put.
claude reins
08 Jan 2018
The benefits keep pouring in......... They come from all corners of the globe. Loads and loads of medical centres.They come with benefits which can be covered by 3 simple advantages - non-invasive (and you only have to speak to someone who has had an invasive biopsy in the two key areas this company is focusing on - breast cancer and prostate cancer - to understand what a benefit that is!); ever increasing value of information to help tailor specific treatments to individual cancer patients; and last but not least there are huge savings to be made from non-invasive biopsy and savings on inappropriate treatments.Angle have recently been teaming up with others - either by relatively small acquisitions - or more importantly by specific agreements with larger organizations to help market the products mre effectively, the most recent one being Philips!The broker - admittedly the housebroker finncap - is giving a target of around double the current price.What's not to like?It is amazing to me that the share price languishes where it is. It wont be for long, all IMHO of course. To anyone who wants to make some money in th next 12-24months - and I believe it will be by a takeover - then I suggest you watch the following interview, date Nov 2017. [link] or go on to the website for more information under investor relations eg on several major shareholders et
autpaxautbellum
11 Dec 2017
Re: Up Presentation of breast cancer research on Wednesday and hopefully other findings to be revealed.
millwallfan
11 Dec 2017
Up Relatively low volume but big rise s o wonder what's driving this and will it be sustained into a new share price range with mid 50 bottom????
autpaxautbellum
08 Dec 2017
RNS today This must put AGL clearly on the radar.
Good money after bad
30 Nov 2017
Re: Hooray Me too...break even at 46p.Averaged down from 80p.Gonna be an interesting ride from here but I’m prepared to drop into the red again if there is no news for a length on time.
millwallfan
30 Nov 2017
Hooray Back to break even - hopefully onwards and upwards!
autpaxautbellum
28 Nov 2017
RNS today More good technical progress.Various buys reported late yesterday - must be time for the sp to move back up.
millwallfan
24 Nov 2017
Re: Philips Claude et al. I have just submitted this on the company website contact point.I hold shares in the company. Can you please advise me when commercialisation of the Parsortix process commences will the income generated be based on 'one off' from sales of the machine to hospitals/clinics etc OR a fee 'per test' OR a combination of both. Thank you
claude reins
23 Nov 2017
Re: Philips Have you asked the CEO or the FD? Might be a good idea. I will if you will!
